Biovica’s DiviTumTKa shows strong capabilities in malignant melanoma

May 20, 2021 - Biovica, active in cancer diagnostics, today announces that DiviTumTKa shows prognostic and predictive capabilities in metastatic cutaneous melanoma patients undergoing immunotherapy. These results from a new study at Karolinska University Hospital will be presented at the upcoming ASCO annual meeting, June 4-8, 2021.

2021-05-20T06:00:00+02:00May 20th, 2021 06:00|

Biovica strengthens the management team

Biovica, active in cancer diagnostics, today announced that the company has strengthened the management team with Helle Fisker as new commercial manager and Joakim Arwidson as new quality and regulatory manager.

2021-04-29T09:00:00+02:00April 29th, 2021 09:00|

Biovica’s DiviTumTKa prognostic for long-term outcome

Biovica, active in cancer diagnostics, today announced that the results from the breast cancer study PROMIX at Karolinska University Hospital is published in the scientific journal ESMO Open. The study showed that testing for TKa levels during early treatment is prognostic for the long-term outcome of preoperative chemotherapy.

2021-03-11T10:10:00+01:00March 11th, 2021 10:10|

Nomination Committee for Biovica for the 2021 Annual General Meeting

The Nomination Committee prior to the 2021 Annual General Meeting will consist of three members, who shall represent the two shareholders with the most number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2020, and the Chairman of the Board. The Nomination Committee then appoints a chairman among its members.

2021-02-26T07:00:00+01:00February 26th, 2021 07:00|